Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRADLEY MONK

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1487734646
CMS profile
249435
Location
WEST PALM BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$395,558.79

244 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $145,367.99 76
Seagen Inc. $45,775.84 33
AstraZeneca Pharmaceuticals LP $42,291.47 29
Genmab U.S., Inc. $34,470.59 30
Merck Sharp & Dohme LLC $32,760.72 13
Regeneron Pharmaceuticals, Inc. $18,262.24 16
AstraZeneca UK Limited $16,440.00 3
Myriad Genetic Laboratories, Inc. $16,003.50 15
Clovis Oncology, Inc. $15,793.24 8
EISAI INC. $13,011.86 4
Novocure Inc. $3,807.30 6
Novocure GmbH $3,195.00 2
Aadi Bioscience, Inc. $2,982.13 3
Eisai Co., Ltd. $2,340.00 1
Novartis Pharmaceuticals Corporation $2,170.00 1
UroGen Pharma, Inc. $700.00 1
Karyopharm Therapeutics Inc. $119.28 1
Corcept Therapeutics $54.69 1
E.R. Squibb & Sons, L.L.C. $12.94 1

Page 5 of 5; records 201–244 of 244 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRADLEY MONK

NPI 1487734646 · CMS profile ID 249435

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

WEST PALM BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–244 of 244 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487734646?year=2022&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRADLEY MONK, NPI 1487734646, CMS profile ID 249435. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–244 of 244 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487734646?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). BRADLEY MONK, NPI 1487734646, CMS profile ID 249435. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–244 of 244 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487734646?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
BRADLEY MONK, NPI 1487734646, CMS profile ID 249435, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–244 of 244 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1487734646?year=2022&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

244 matching records · $395,558.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 244 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–244 of 244.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genmab U.S., Inc. $70.4302/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582107 CMS
Genmab U.S., Inc. $27.0002/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582087 CMS
Genmab U.S., Inc. $63.5902/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582091 CMS
Genmab U.S., Inc. $328.6102/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582095 CMS
Genmab U.S., Inc. $122.4102/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582099 CMS
Myriad Genetic Laboratories, Inc. $575.0002/10/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937234953 CMS
Myriad Genetic Laboratories, Inc. $862.5002/10/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937239541 CMS
Genmab U.S., Inc. $307.5002/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582075 CMS
Genmab U.S., Inc. $177.6502/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582079 CMS
Genmab U.S., Inc. $7,170.0002/09/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582083 CMS
Genmab U.S., Inc. $31.1902/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582067 CMS
Genmab U.S., Inc. $30.7202/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582071 CMS
GlaxoSmithKline, LLC. $91.0002/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944479307 CMS
Genmab U.S., Inc. $138.9001/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582059 CMS
Genmab U.S., Inc. $120.8901/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582063 CMS
Genmab U.S., Inc. $233.8301/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582055 CMS
Regeneron Pharmaceuticals, Inc. $655.0001/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927746489 CMS
Regeneron Pharmaceuticals, Inc. $327.5001/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927746497 CMS
Regeneron Pharmaceuticals, Inc. $1,310.0001/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927746503 CMS
Regeneron Pharmaceuticals, Inc. $327.5001/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927746509 CMS
Genmab U.S., Inc. $7,800.0001/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582051 CMS
AstraZeneca Pharmaceuticals LP $1,370.0001/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914667009 CMS
AstraZeneca Pharmaceuticals LP $1,050.0001/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915422517 CMS
AstraZeneca Pharmaceuticals LP $200.0001/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915629461 CMS
AstraZeneca Pharmaceuticals LP $5,500.0001/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915890189 CMS
Genmab U.S., Inc. $7,170.0001/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582047 CMS
Merck Sharp & Dohme LLC $4,270.0001/19/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944442505 CMS
Seagen Inc. $527.5001/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904110365 CMS
Genmab U.S., Inc. $568.2101/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582043 CMS
GlaxoSmithKline, LLC. $14,950.0001/18/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944479493 CMS
Genmab U.S., Inc. $187.9601/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582039 CMS
Novocure Inc. $1,800.0001/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953395391 CMS
Regeneron Pharmaceuticals, Inc. $655.0001/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927746475 CMS
Regeneron Pharmaceuticals, Inc. $655.0001/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927746483 CMS
GlaxoSmithKline, LLC. $29.0001/12/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944479315 CMS
GlaxoSmithKline, LLC. $14.5201/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944479511 CMS
Genmab U.S., Inc. $139.6501/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582027 CMS
Genmab U.S., Inc. $280.3801/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582031 CMS
Genmab U.S., Inc. $95.4001/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 921582035 CMS
Myriad Genetic Laboratories, Inc. $1,400.0001/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937247395 CMS
UroGen Pharma, Inc. $700.0001/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907971811 CMS
GlaxoSmithKline, LLC. $61.0001/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944479355 CMS
GlaxoSmithKline, LLC. $39.6201/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944479437 CMS
GlaxoSmithKline, LLC. $4,800.0001/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944479473 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $560,858.86 532
PY2020 $298,974.09 202
PY2021 $344,036.80 224
PY2022 $395,558.79 244
PY2023 $329,222.43 213
PY2024 $306,030.68 242
PY2025 $306,026.06 246

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,063.41 3
PY2025 Principal investigator $439,423.71 22
PY2024 Recipient $3,095.22 4
PY2024 Principal investigator $76,698.65 17
PY2023 Recipient $142.60 1
PY2023 Principal investigator $1,051,207.42 102
PY2022 Recipient $7,369.82 22
PY2022 Principal investigator $1,488,437.47 192
PY2021 Recipient $66,072.29 10
PY2021 Principal investigator $1,383,091.36 373
PY2020 Recipient $277.54 1
PY2020 Principal investigator $1,442,281.10 170
PY2019 Recipient $463.47 10
PY2019 Principal investigator $2,049,430.60 358

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genmab U.S., Inc. $1,568.57 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933818
Principal investigator 1 Genmab U.S., Inc. $15,078.70 12/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235934549
Principal investigator 1 Genmab U.S., Inc. $3,101.91 12/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933948
Principal investigator 1 Verastem, Inc. $56.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
RAMP 201 - GOG-3052 No dispute reported 06/30/2026 1207992695
Principal investigator 1 Verastem, Inc. $33,658.68 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
RAMP 201 - GOG-3052 No dispute reported 06/30/2026 1207992729
Principal investigator 1 Verastem, Inc. $404.00 12/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
RAMP 201 - GOG-3052 No dispute reported 06/30/2026 1207992731
Principal investigator 1 Genmab U.S., Inc. $8,389.60 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235933771
Principal investigator 1 Genmab U.S., Inc. $1,751.10 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235934552
Principal investigator 1 Genmab U.S., Inc. $334,157.65 11/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235934569
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,000.00 10/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
An Open Label, Randomized, Multicenter, controlled, Phase III Study of First-line Trastuzumab Deruxtecan (T-DXd) monotherapy versus SoC in patients with HER2-expressing (IHC 3+/IHC 2+) Mismatch Repair Proficient (pMMR) primary advanced or recurrent Endometrial Cancer No dispute reported 06/30/2026 1185543692
Principal investigator 1 BeOne Medicines Ltd. $300.00 10/21/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190332157
Principal investigator 1 BeOne Medicines Ltd. $1,950.00 09/16/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190332153
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 08/12/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190332155
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 07/15/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190332151
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 06/17/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190339289
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 06/10/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190339279
Principal investigator 1 BeOne Medicines Ltd. $5,100.00 06/10/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190339283
Principal investigator 1 BeiGene, Ltd. $8,907.50 05/05/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190323964
Principal investigator 1 BeiGene, Ltd. $2,500.00 04/22/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190323962
Recipient PFIZER INC. $940.00 04/21/2025 Covered Recipient Physician TUCATINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228829207
Principal investigator 1 BeiGene, Ltd. $2,500.00 04/08/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190323960
Principal investigator 1 BeiGene, Ltd. $2,500.00 02/11/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190320294
Recipient PFIZER INC. $330.00 02/11/2025 Covered Recipient Physician TUCATINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228829199
Principal investigator 1 BeiGene, Ltd. $2,500.00 01/21/2025 Non-covered Recipient Entity
Florida Cancer Specialist (SCRI) - Fort Myers
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors No dispute reported 06/30/2026 1190320292
Recipient Regeneron Pharmaceuticals, Inc. $793.41 01/09/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184120601